BioSpace News Archive

United States Pharmacopeia (USP), an independent, scientific nonprofit organization, is pleased to announce the acquisition of Pharmatech Associates, Inc.

Scientists at the University of North Carolina at Chapel Hill School of Medicine and colleagues have demonstrated that variants in the SPTBN1 gene can alter neuronal architecture, dramatically affecting their function and leading to a rare, newly defined neurodevelopmental syndrome in children.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company approved the grant of equity awards to one new employee with a grant date of July 1, 2021, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Eyenovia, Inc., a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print platform technology, announced that management will present a corporate overview and host one-one-one meetings at the Ladenburg Thalmann 2021 Healthcare Conference, being held virtually July 13-14, 2021, and host one-on-meetings at the William Blair Biotech Focus Conference 2021, being held virtually July 14-15, 2021.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the FDA 510(k) clearance of its 7D Percutaneous Spine Module for minimally invasive surgery.

Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Steven O’Day, MD, Chief Medical Officer of Agenus, will participate in a panel discussion at the William Blair Biotech Focus Conference 2021

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that on July 1, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 259,550 shares of Curis common stock to fifteen new employees, with a grant date of July 1, 2021.

Blueprint Medicines Corporation announced that, effective on July 1, 2021, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 25,762 shares of its common stock and an aggregate of 12,880 restricted stock units to 12 new employees under Blueprint Medicines’ 2020 Inducement Plan.

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced that the Company resumed its partially adjourned 2021 annual stockholders meeting on July 7, 2021, solely with respect to Proposal 2 set forth in its Definitive Proxy Statement, dated April 26, 2021, relating to the increase in the Company’s authorized shares of common stock.

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has joined the Rare Disease Company Coalition,